Illumina, Inc. (NASDAQ:ILMN) is Eagle Health Investments LP’s 3rd Largest Position

Eagle Health Investments LP reduced its stake in Illumina, Inc. (NASDAQ:ILMN) by 11.4% during the 4th quarter, HoldingsChannel reports. The firm owned 343,361 shares of the life sciences company’s stock after selling 43,993 shares during the period. Illumina accounts for 11.2% of Eagle Health Investments LP’s portfolio, making the stock its 3rd biggest position. Eagle Health Investments LP’s holdings in Illumina were worth $45,883,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Golden State Wealth Management LLC purchased a new position in Illumina in the 4th quarter valued at $32,000. Versant Capital Management Inc lifted its stake in shares of Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 146 shares during the period. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of Illumina in the fourth quarter valued at about $45,000. Assetmark Inc. increased its stake in shares of Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after acquiring an additional 296 shares during the period. Finally, Lee Danner & Bass Inc. purchased a new position in Illumina during the fourth quarter worth about $48,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Down 5.4 %

Shares of NASDAQ ILMN opened at $82.83 on Thursday. The firm has a market cap of $13.12 billion, a P/E ratio of -10.79, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. Illumina, Inc. has a 1 year low of $80.18 and a 1 year high of $156.66. The firm’s 50 day moving average price is $105.03 and its 200 day moving average price is $127.40.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, sell-side analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Guggenheim dropped their target price on Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. TD Cowen lowered Illumina from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $177.00 to $140.00 in a report on Friday, February 7th. Hsbc Global Res downgraded Illumina from a “strong-buy” rating to a “hold” rating in a report on Friday, February 28th. HSBC cut shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target on the stock. in a research note on Friday, February 28th. Finally, Morgan Stanley reduced their price objective on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $140.90.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.